Bergenbio ASA - ESG Rating & Company Profile powered by AI
The analysis of Bergenbio ASA employs intelligence from across the web and also from available disclosures by Bergenbio ASA. This ESG rating includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Life on Land'. This Sustainability assessment for Bergenbio ASA indicates its reporting of the United Nations Sustainable Development Goals.
Bergenbio ASA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 5.3, social score of 1.6 and governance score of 2.0.
3.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1309 | Willow Biosciences Inc | 3.1 | Medium |
| 1309 | biOasis Technologies Inc | 3.1 | Medium |
| 1336 | Bergenbio ASA | 3.0 | Medium |
| 1336 | BridgeBio Pharma Inc | 3.0 | Medium |
| 1336 | Absci Corp | 3.0 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Bergenbio ASA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Bergenbio ASA disclose current and historical energy intensity?
Sign up for free to unlockDoes Bergenbio ASA report the average age of the workforce?
Sign up for free to unlockDoes Bergenbio ASA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Bergenbio ASA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Bergenbio ASA disclose cybersecurity risks?
Sign up for free to unlockDoes Bergenbio ASA offer flexible work?
Sign up for free to unlockDoes Bergenbio ASA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Bergenbio ASA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Bergenbio ASA conduct supply chain audits?
Sign up for free to unlockDoes Bergenbio ASA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Bergenbio ASA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Bergenbio ASA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Bergenbio ASA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Bergenbio ASA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Bergenbio ASA disclose water use targets?
Sign up for free to unlockDoes Bergenbio ASA have careers partnerships with academic institutions?
Sign up for free to unlockDid Bergenbio ASA have a product recall in the last two years?
Sign up for free to unlockDoes Bergenbio ASA disclose incidents of discrimination?
Sign up for free to unlockDoes Bergenbio ASA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Bergenbio ASA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Bergenbio ASA disclose parental leave metrics?
Sign up for free to unlockDoes Bergenbio ASA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Bergenbio ASA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Bergenbio ASA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Bergenbio ASA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Bergenbio ASA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Bergenbio ASA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Bergenbio ASA involved in embryonic stem cell research?
Sign up for free to unlockDoes Bergenbio ASA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Bergenbio ASA disclose its waste policy?
Sign up for free to unlockDoes Bergenbio ASA report according to TCFD requirements?
Sign up for free to unlockDoes Bergenbio ASA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Bergenbio ASA disclose energy use targets?
Sign up for free to unlockDoes Bergenbio ASA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Bergenbio ASA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Bergenbio ASA
These potential risks are based on the size, segment and geographies of the company.
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.